Description: MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. The company was incorporated in 2018 and is headquartered in Kelowna, Canada.
Home Page: www.myndsciences.com
Unit 150
Port Coquitlam,
BC
V3C 2B2
Canada
Phone:
403 559 6779
Officers
| Name | Title |
|---|---|
| Dr. Wilfred A. Jefferies | Co-Founder & Chief Science Officer |
| Mr. Lih-Ming Tam | CFO & Senior Controller |
| Dr. Lyle Oberg M.D. | Co-Founder & Executive Chairman of the Board |
| Mr. John Campbell | President,CEO & Director |
| Dr. Chaahat S.B Singh | Senior Operations & Research Manager |
| Mr. Luke Warkentin | Vice President of Corporate Development |
| Dr. Iryna Saranchova M.D., Ph.D. | Chief Clinical Officer |
Exchange: OTCQB
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 999999.9999 |
| IPO Date: | |
| Fiscal Year End: | October |
| Full Time Employees: | 0 |